• Participants in https://clinicaltrials.gov/study/NCT05882045 must have established cardiovascular disease, defined as prior myocardial infarction, prior ischemic or hemorrhagic stroke, or symptomatic peripheral arterial disease.
In other words, LLY’s commitment to Retatrutide as a treatment for obesity per se may somewhat less than it seems at first glance.
Moreover, in #msg-173951612 I misspoke and need to clarify. What I meant to say is, “I’m going out on a limb by asserting that LLY’s Retatrutide (a/k/a “triple G”) will not make it to market as a treatment for obesity.”
Your reply allowed me to recognize my misstatement, so thank you!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.